Oscar Chalupsky, 63, says Talvey response shows why UAE oncology approvals matter

Oscar Chalupsky, the 63-year-old South African surfski champion, said his blood markers improved after starting Talvey, a last-line immunotherapy for advanced multiple myeloma, according to Briefly News.

The story matters in the UAE because advanced oncology care can move faster than benefit design, drug availability and pre-authorisation workflows. In Dubai, that puts the practical burden on clinics regulated by the Dubai Health Authority (DHA), insurers such as Sukoon where applicable, and patients who need to know whether a named medicine is on formulary before admission.

What happened in South Africa

Chalupsky has been treated for multiple myeloma, a blood and bone marrow cancer, and an aggressive skin cancer. The latest update said he had started Talvey after doctors ruled out CAR-T therapy because of advanced disease. Briefly News reported that he had a reaction after the first dose, then had better results after a second dose and blood transfusion.

“I am moving in the right direction.” — Oscar Chalupsky, quoted by Briefly News

Talvey is the brand name for talquetamab. It is a bispecific antibody used in relapsed or refractory multiple myeloma in specified patient groups. For UAE operators, the immediate question is less the social-media update and more the operating pathway: consultant order, insurer pre-authorisation, pharmacy procurement, inpatient monitoring and adverse-event readiness.

Dubai clinics need approval discipline

DHA-licensed providers should treat a case like this as a reminder to audit two workflows: high-cost oncology authorisations and inpatient monitoring for immunotherapy reactions. Dubai residents on minimum-benefit policies may have an annual benefit limit of AED 150,000, according to the UAE Government portal’s health insurance guidance, while advanced oncology medicines can require separate plan checks and written insurer approval.

For CEOs and CFOs, the P&L risk is denial after treatment starts. For COOs and medical directors, the risk is a patient being admitted before the drug, dose schedule and observation requirement are confirmed. A practical Dubai checklist should include:

• Confirm the member’s emirate of visa and regulator pathway before booking treatment.
• Ask the insurer for written approval naming the drug, dose, cycle count and facility.
• Check whether inpatient step-up dosing, transfusion support or ICU backup is required.
• Record adverse-event protocols for cytokine release syndrome where the treating team identifies that risk.

Patients should ask for an estimate in writing because UAE oncology costs vary by drug, weight-based dose, setting and network status. Where a clinic cannot quote a full-cycle price, it should at least give the consultation fee, expected diagnostic tests, infusion-day facility charge and the insurer approval reference.

Abu Dhabi and the northern emirates

In Abu Dhabi and Al Ain, the relevant regulator is the Department of Health – Abu Dhabi (DOH). DOH has issued oncology service and centre-of-excellence standards, and in 2024 said its precision medicine programme had supported 256 Emirati cancer patients since launch. For Daman and Thiqa members, providers still need to test the exact benefit, network and prior-approval rules before counselling patients on access.

In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, oncology providers sit under the Ministry of Health and Prevention (MOHAP) or relevant local licensing routes. MOHAP also supervises national cancer registry reporting, which makes accurate coding and cancer notification more than an administrative task. It affects planning for drugs, specialists and screening capacity.

The patient lesson is direct. A famous athlete’s update can make patients ask for Talvey, CAR-T therapy or other advanced treatments by name. UAE clinics should respond with eligibility criteria, licensed specialist review and insurer-specific approval steps. Patients should bring pathology reports, treatment history, imaging, medication lists and insurance cards to the first oncology visit.

The next place to check is the UAE Open Healthcare Directory, which lists UAE-licensed medical oncology providers and facilities. Start with licensed oncology capacity in Dubai, then compare Abu Dhabi, Al Ain and the northern emirates by regulator, insurer network and treatment availability.